| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 14 | 2024 | 872 | 3.650 |
Why?
|
| Laryngeal Neoplasms | 6 | 2016 | 85 | 2.590 |
Why?
|
| Neoplastic Stem Cells | 6 | 2016 | 329 | 1.690 |
Why?
|
| Prostatic Neoplasms | 13 | 2020 | 1395 | 1.640 |
Why?
|
| Biomarkers, Tumor | 9 | 2020 | 1561 | 1.550 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 743 | 1.510 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 1239 | 1.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2017 | 1932 | 0.970 |
Why?
|
| Chordoma | 3 | 2013 | 18 | 0.850 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 189 | 0.840 |
Why?
|
| Gene Expression Profiling | 11 | 2024 | 1773 | 0.830 |
Why?
|
| Mutation | 6 | 2019 | 5945 | 0.830 |
Why?
|
| Alternative Splicing | 2 | 2019 | 296 | 0.720 |
Why?
|
| Mutation, Missense | 3 | 2015 | 890 | 0.690 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2015 | 57 | 0.670 |
Why?
|
| Transfection | 5 | 2015 | 948 | 0.610 |
Why?
|
| rab3 GTP-Binding Proteins | 1 | 2019 | 7 | 0.600 |
Why?
|
| Optic Atrophy | 1 | 2019 | 46 | 0.580 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 964 | 0.550 |
Why?
|
| Cataract | 1 | 2019 | 144 | 0.540 |
Why?
|
| Skin Abnormalities | 2 | 2014 | 35 | 0.530 |
Why?
|
| Microcephaly | 3 | 2019 | 344 | 0.520 |
Why?
|
| Machine Learning | 1 | 2020 | 325 | 0.510 |
Why?
|
| CHARGE Syndrome | 1 | 2015 | 8 | 0.480 |
Why?
|
| Centrioles | 1 | 2015 | 5 | 0.470 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 30 | 0.470 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 88 | 0.470 |
Why?
|
| White Coat Hypertension | 1 | 2015 | 10 | 0.460 |
Why?
|
| Cell Proliferation | 5 | 2015 | 2397 | 0.460 |
Why?
|
| Usher Syndromes | 1 | 2015 | 12 | 0.460 |
Why?
|
| Saliva | 1 | 2015 | 130 | 0.450 |
Why?
|
| Decision Making | 1 | 2020 | 666 | 0.450 |
Why?
|
| Hypogonadism | 1 | 2019 | 318 | 0.440 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 2 | 0.440 |
Why?
|
| Male | 34 | 2024 | 62788 | 0.440 |
Why?
|
| Cornea | 1 | 2019 | 551 | 0.440 |
Why?
|
| Dwarfism | 1 | 2015 | 102 | 0.440 |
Why?
|
| Up-Regulation | 5 | 2015 | 827 | 0.430 |
Why?
|
| DNA Helicases | 1 | 2015 | 229 | 0.430 |
Why?
|
| Ephrin-B1 | 1 | 2013 | 9 | 0.410 |
Why?
|
| Foot Deformities | 1 | 2013 | 4 | 0.410 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2018 | 1005 | 0.410 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2020 | 524 | 0.400 |
Why?
|
| Tyrosinemias | 1 | 2013 | 7 | 0.400 |
Why?
|
| Skull Base Neoplasms | 1 | 2013 | 37 | 0.390 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2012 | 12 | 0.390 |
Why?
|
| Humans | 45 | 2024 | 127321 | 0.390 |
Why?
|
| Neutropenia | 1 | 2014 | 198 | 0.390 |
Why?
|
| Cochlea | 1 | 2013 | 88 | 0.380 |
Why?
|
| Lymph Nodes | 1 | 2014 | 374 | 0.370 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2012 | 104 | 0.370 |
Why?
|
| Limb Deformities, Congenital | 1 | 2013 | 109 | 0.370 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1045 | 0.360 |
Why?
|
| Middle Aged | 15 | 2024 | 27815 | 0.360 |
Why?
|
| Lymphocytes | 1 | 2013 | 355 | 0.350 |
Why?
|
| Craniofacial Abnormalities | 1 | 2013 | 252 | 0.350 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 155 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 4 | 2016 | 984 | 0.340 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 656 | 0.340 |
Why?
|
| Proteins | 2 | 2015 | 1019 | 0.330 |
Why?
|
| Phenotype | 5 | 2019 | 4307 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1709 | 0.310 |
Why?
|
| Prognosis | 5 | 2018 | 4799 | 0.310 |
Why?
|
| Female | 24 | 2024 | 68630 | 0.300 |
Why?
|
| Pedigree | 4 | 2019 | 1656 | 0.300 |
Why?
|
| Case-Control Studies | 5 | 2024 | 3324 | 0.300 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 591 | 0.290 |
Why?
|
| Prostatectomy | 3 | 2020 | 309 | 0.290 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 677 | 0.280 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 631 | 0.280 |
Why?
|
| ROC Curve | 3 | 2020 | 587 | 0.270 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 1891 | 0.270 |
Why?
|
| Adult | 13 | 2024 | 30542 | 0.260 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 50 | 0.260 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2004 | 57 | 0.260 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 431 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2015 | 3502 | 0.260 |
Why?
|
| Turkey | 2 | 2019 | 64 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1232 | 0.240 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 18 | 0.230 |
Why?
|
| AC133 Antigen | 2 | 2016 | 35 | 0.230 |
Why?
|
| Genetic Therapy | 2 | 2014 | 683 | 0.230 |
Why?
|
| Apoptosis | 5 | 2015 | 1823 | 0.220 |
Why?
|
| Down-Regulation | 3 | 2015 | 649 | 0.220 |
Why?
|
| Genes, Dominant | 1 | 2004 | 241 | 0.200 |
Why?
|
| Electroconvulsive Therapy | 1 | 2024 | 81 | 0.200 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1759 | 0.180 |
Why?
|
| Schizophrenia | 1 | 2024 | 320 | 0.170 |
Why?
|
| Adenoviridae | 1 | 2004 | 573 | 0.170 |
Why?
|
| Tissue Kallikreins | 1 | 2020 | 7 | 0.170 |
Why?
|
| Normal Distribution | 1 | 2020 | 19 | 0.160 |
Why?
|
| Aged | 6 | 2015 | 20431 | 0.160 |
Why?
|
| Exome | 2 | 2015 | 1064 | 0.160 |
Why?
|
| Probability | 1 | 2020 | 307 | 0.160 |
Why?
|
| Infant | 8 | 2016 | 12806 | 0.160 |
Why?
|
| Genes, p53 | 1 | 2020 | 213 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 2856 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2015 | 1015 | 0.150 |
Why?
|
| INDEL Mutation | 1 | 2019 | 91 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 252 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 126 | 0.140 |
Why?
|
| Child | 8 | 2019 | 25296 | 0.140 |
Why?
|
| Child, Preschool | 7 | 2016 | 14462 | 0.140 |
Why?
|
| Siblings | 1 | 2019 | 202 | 0.140 |
Why?
|
| DNA Damage | 1 | 2020 | 498 | 0.130 |
Why?
|
| Homozygote | 1 | 2019 | 540 | 0.130 |
Why?
|
| Melanoma | 1 | 2004 | 898 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 2311 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1387 | 0.130 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 21 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 880 | 0.120 |
Why?
|
| Serum Globulins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Heterozygote | 2 | 2015 | 690 | 0.120 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 727 | 0.120 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 41 | 0.120 |
Why?
|
| Phorbols | 1 | 2015 | 5 | 0.120 |
Why?
|
| Platelet Count | 1 | 2015 | 132 | 0.120 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 58 | 0.120 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2015 | 90 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 90 | 0.110 |
Why?
|
| G1 Phase | 1 | 2015 | 65 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2015 | 88 | 0.110 |
Why?
|
| Prostate | 1 | 2017 | 406 | 0.110 |
Why?
|
| RNA Interference | 1 | 2016 | 493 | 0.110 |
Why?
|
| De Lange Syndrome | 1 | 2015 | 43 | 0.110 |
Why?
|
| Cell Differentiation | 4 | 2011 | 1868 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2891 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 39 | 0.110 |
Why?
|
| Hepatitis B, Chronic | 1 | 2015 | 87 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 1206 | 0.110 |
Why?
|
| Microarray Analysis | 1 | 2015 | 225 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 52 | 0.110 |
Why?
|
| Fibroblasts | 2 | 2015 | 820 | 0.110 |
Why?
|
| Phosphotransferases | 1 | 2014 | 33 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 207 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 236 | 0.110 |
Why?
|
| Codon, Nonsense | 1 | 2015 | 139 | 0.110 |
Why?
|
| Cell Movement | 2 | 2015 | 851 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 54 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2015 | 325 | 0.110 |
Why?
|
| Retinitis Pigmentosa | 1 | 2015 | 89 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2015 | 684 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 273 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2013 | 2541 | 0.100 |
Why?
|
| RNA, Transfer | 1 | 2014 | 68 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 216 | 0.100 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 64 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 110 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 781 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6694 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 94 | 0.100 |
Why?
|
| Oncogenes | 1 | 2014 | 162 | 0.100 |
Why?
|
| Cutis Laxa | 1 | 2013 | 10 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 198 | 0.100 |
Why?
|
| Algorithms | 1 | 2020 | 1635 | 0.100 |
Why?
|
| Cell Separation | 1 | 2014 | 219 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 359 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 425 | 0.100 |
Why?
|
| Exons | 1 | 2015 | 757 | 0.100 |
Why?
|
| Karyotype | 1 | 2013 | 29 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 130 | 0.100 |
Why?
|
| Hearing Loss | 1 | 2015 | 199 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1291 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 27 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1598 | 0.100 |
Why?
|
| Ichthyosis | 1 | 2012 | 30 | 0.100 |
Why?
|
| Dermatitis | 1 | 2012 | 26 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 117 | 0.100 |
Why?
|
| Hamartoma | 1 | 2013 | 49 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 571 | 0.090 |
Why?
|
| Stem Cells | 2 | 2007 | 682 | 0.090 |
Why?
|
| Skin | 1 | 2015 | 517 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 637 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 900 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 410 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2018 | 4977 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2014 | 415 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2014 | 267 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 47 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2014 | 338 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 1484 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2012 | 220 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 689 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2543 | 0.090 |
Why?
|
| Base Sequence | 1 | 2015 | 2759 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 394 | 0.090 |
Why?
|
| Vidarabine | 1 | 2011 | 85 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2015 | 1400 | 0.090 |
Why?
|
| Etoposide | 1 | 2011 | 109 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 398 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 67 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2013 | 755 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 101 | 0.090 |
Why?
|
| Benzamides | 1 | 2011 | 120 | 0.090 |
Why?
|
| Disease Progression | 2 | 2015 | 2120 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 1727 | 0.090 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 422 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3587 | 0.080 |
Why?
|
| Vincristine | 1 | 2011 | 190 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2014 | 1498 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 123 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 219 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2013 | 201 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 398 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2020 | 4485 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 333 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2011 | 286 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 172 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 830 | 0.080 |
Why?
|
| Cisplatin | 1 | 2011 | 269 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2011 | 324 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2016 | 1032 | 0.080 |
Why?
|
| Piperazines | 1 | 2011 | 256 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 439 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2898 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 317 | 0.080 |
Why?
|
| Cell Survival | 3 | 2012 | 840 | 0.080 |
Why?
|
| Family | 1 | 2012 | 580 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 711 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 1508 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 101 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 874 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2011 | 407 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 2598 | 0.070 |
Why?
|
| Computational Biology | 1 | 2013 | 835 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1068 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1205 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 2745 | 0.070 |
Why?
|
| Cartilage | 1 | 2007 | 50 | 0.070 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 28 | 0.060 |
Why?
|
| Chondrogenesis | 1 | 2007 | 27 | 0.060 |
Why?
|
| Somatomedins | 1 | 2006 | 33 | 0.060 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 37 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2007 | 47 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 776 | 0.060 |
Why?
|
| Neurites | 1 | 2006 | 42 | 0.060 |
Why?
|
| Ganglia, Spinal | 1 | 2006 | 62 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 108 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2007 | 162 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2006 | 224 | 0.060 |
Why?
|
| Cell Division | 2 | 2004 | 719 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 330 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8365 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 213 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2014 | 2343 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 2586 | 0.050 |
Why?
|
| G2 Phase | 1 | 2004 | 38 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 1 | 2004 | 35 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 477 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 82 | 0.050 |
Why?
|
| Oxygen | 1 | 2007 | 541 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 3039 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 42 | 0.050 |
Why?
|
| Animals | 8 | 2014 | 33194 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 94 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 87 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2006 | 676 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 148 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 973 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7402 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 283 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2015 | 17066 | 0.040 |
Why?
|
| Time Factors | 2 | 2006 | 6163 | 0.040 |
Why?
|
| Mice | 7 | 2014 | 17685 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3263 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2007 | 290 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 972 | 0.030 |
Why?
|
| Globulins | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2007 | 570 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2015 | 122 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 302 | 0.030 |
Why?
|
| Exonucleases | 1 | 2015 | 27 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 30 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2014 | 27 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2015 | 74 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 113 | 0.030 |
Why?
|
| Cerebrum | 1 | 2014 | 33 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 156 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2014 | 84 | 0.030 |
Why?
|
| Hypertelorism | 1 | 2013 | 12 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 205 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2015 | 481 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2013 | 103 | 0.020 |
Why?
|
| Syndrome | 1 | 2015 | 1137 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 291 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 4512 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 1237 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 808 | 0.020 |
Why?
|
| Adolescent | 3 | 2015 | 20150 | 0.020 |
Why?
|
| Craniosynostoses | 1 | 2013 | 139 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2015 | 763 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 532 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 9696 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 606 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1765 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2007 | 120 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 302 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 437 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2006 | 3718 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 5 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 34 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 85 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2007 | 106 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 87 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 120 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 74 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3235 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2006 | 230 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 123 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 156 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 253 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 4445 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 420 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 445 | 0.010 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 578 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2003 | 38 | 0.010 |
Why?
|
| Osteopontin | 1 | 2003 | 51 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2003 | 67 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 361 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 224 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 2565 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 578 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1380 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 332 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 713 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 1537 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 1609 | 0.010 |
Why?
|